The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Burstead - just wish to welcome you to the board as the latest deramper.
You have a long way to go if you think you're fooling most LTH's. I like how you're agreeing with Doc but attempting to push the negativity several yards further down the road, by questioning Polygon.
Anyone wondering, just read their post history.
Not looking to fight, Docdaneeka.
I still remain positive about what happened today. Through other posters we know that there are regular meetings surrounding SNG001 on ACTIV-2. I see the update on the timeline in particular as the most promising. They wouldn't have given that new estimate if they didn't envisage it continuing again. That was my point and that is why I added more to my main holding, plus the trading account.
I have been very nervous about the pause until today. This gives me comfort that there is a vision of when they see the trial ending.
My last post to you, Docdaneeka.
Read my posts properly. I know the trial is paused. I am excited about the fact they have given it a new timeline. This lines up to somebody on Twitter's email correspondence with their NIH contact.
I am afraid I am not always wrong and I don't suffer fools gladly. I apologise if I hurt your feelings as I know you're very sensitive.
Docdaneeka - let me explain to you like you are 5 years old:
The update was made yesterday on the website of the NIH.
An NIH employee went in and changed the status to "Continuing enrollment/passed interim analysis/Q1 2023".
This is positive as there is a new timeline provided from the previous entry. I view this as good news because it lifts the uncertainty surrounding the "pause".
Unlike you, I do not rely on Matterhorn and Ghia for my information. I make my own my mind up.
Finally, I have a trading account and an account with my main holding. I added to the main holding and decided to trade it using the other.
Shocking attempt at an insult there, Docdaneeka.
It is nice to be in all of the other boards/forums and not have to rely on LSE. I would be screwed if I was to simply sit here and pay attention to your assumptions. You may possess a thesaurus Docdaneeka, but your flowery writing does nothing to help with the actual facts.
Thank you for the quote from GSK. Not like a Big Pharma to try and protect their asset.
I stand by what I wrote Docdaneeka. Update is positive.
I have been trading since the horrific Monday. There is money to be made here in the short term and my losses are massive. Prefer to claw some back than sit and whinge about RM not showing.
I highly doubt you're aware of this:
https://www.theguardian.com/world/2022/mar/10/covid-treatment-sotrovimab-can-cause-drug-resistant-mutation-study-finds
Docdaneeka:
Please post evidence for "Real reason SAB was chucked off is because they have similar drugs that do the same thing and are still working against Omicron."
Where can one find the "real reason"? Or is this just another one of your assumptions?
This is new. To clarify:
Via https: //www.nih.gov/activ/nih-funded-activ/activ-associated-clinical-trials
SNG001 has been updated to "Continuing enrollment/passed interim analysis/Q1 2023"
Per a couple of sources elsewhere, the NIH have been discussing SNG001 on ACTIV-2 for the past couple of weeks. This appears to be the outcome. SNG001 will proceed with the continuation of enrolment of patients and the expected completion is Q1-2023.
Do you have a source for the announcement? It is not reported anywhere.
"TFG Asset Management currently comprises LCM, BentallGreenOak, Polygon, Acasta Partners, Equitix, Hawke’s Point, Tetragon Credit Partners, Banyan Square Partners and Contingency Capital"
https://www.tetragoninv.com/portfolio/tfg-asset-management/acasta
Have to agree. There is also a rumour doing the rounds about a new buyer.
Back to Polygon, somebody mentioned them being able to see something that private investors can't. May have something to do with their field trip to the USA last year.
"This pause is about the pause of large scale production."
No it isn't. Two completely separate things.
The mass production related to a positive SPRINTER trial would have only began in case of an order pre or post EUA. So, what would they be pausing if it never began? I honestly don't understand how somebody can conclude that from what has been announced.